Clinical trials: COVID-19 Prevention
SARS CoV 2 Infection
A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals
This is an open-label study examining the safety and tolerability of sotrovimab, administered in two sequential doses as prophylaxis in immunocompromised patients with impaired humoral immunity against SARS-CoV-2.
- Trial name
- NCT05210101
- Testing
- Sotrovimab
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Sophia Koo, M.D.
COVID-19 Prevention
A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults
The purpose of this study is to demonstrate the non-inferiority (NI) of the humoral immune response of the 4 influenza vaccine strains after concomitant administration of the Ad26.COV2.S vaccine and a seasonal quadrivalent…
- Trial name
- NCT05091307
- Testing
- Ad26.COV2.S, Influenza Vaccine
- Where
- 31 sites in United States, Belgium and 1 more
- Volunteers
- 861 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19, Coronavirus Infection
A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection
This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19
- Conditions
- COVID-19, Coronavirus Infection, Sars-CoV2, Corona Virus Infection
- Trial name
- HELPCOVID-19 (NCT04335084)
- Testing
- Hydroxychloroquine, Vitamin C, Vitamin D
- Where
- United States
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
COVID-19
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.
- Trial name
- NCT04377659
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
COVID-19, Viral Respiratory Illnesses
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2…
- Trial name
- NCT04359680
- Testing
- Nitazoxanide, Vitamin Super B-Complex
- Where
- 26 sites in United States
- Volunteers
- 1,407 people
- Sponsor
- Romark Laboratories L.C.
COVID-19 Respiratory Infection, Acute Respiratory Disease
Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19
It is known that the pretreatment with exogenous interferon blocks SARS-CoV-2 infection, but intervention is much more effective if administered prior to infection.
- Trial name
- NCT05054114
- Testing
- Interferon gamma human recombinant (IFN-G)
- Where
- Russia
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- SPP Pharmaclon Ltd.
COVID-19
Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.
This clinical trial is a single-blind, randomised study to determine the reactogenicity and immunogenicity of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) vaccine (Pfizer-BioNTech) as booster dose in adults, who…
- Trial name
- NCT05265065
- Testing
- Tozinameran - Standard Dose, Tozinameran - Fractional Dose
- Where
- Mongolia
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
SARS-CoV-2
Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial
This is a pragmatic randomized open-label study of the safety and efficacy of the combination of colchicine and Rosuvastatin in addition to standard of care (SOC) compared to SOC alone in hospitalized patients with SARS-CoV-2
- Trial name
- COLSTAT (NCT04472611)
- Testing
- Standard of Care (SOC) and Colchicine+Rosuvastatin
- Where
- 4 sites in United States
- Volunteers
- 250 people
- Sponsor
- Yale University
COVID-19, SARS-CoV-2 Infection
A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects
Trial to evaluate the safety and immunogenicity of one or two boosting doses of Comirnaty or one dose of BNT162b2s01 (Variant of concern [VOC] strain B.1.351) in BNT162-01 trial participants, or two boosting doses of Comirnaty in…
- Trial name
- NCT04949490
- Testing
- BNT162b2s01, BNT162b2
- Where
- 4 sites in Germany
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019.
- Trial name
- NCT04712110
- Testing
- TAK-019
- Where
- 2 sites in Japan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Takeda
COVID-19, Pharmacokinetics
Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis
This is a phase I randomized, placebo-controlled, single site to assess the local and systemic safety of intranasal Q-Griffithsin (Q-GRFT) after 14 doses in approximately 45 adult participants.
- Conditions
- COVID-19, Pharmacokinetics, Safety
- Trial name
- NCT05180500
- Testing
- Q-Griffithsin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sharon Hillier
COVID-19, SARS-CoV2
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479 prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease - 2019 (COVID-19).
- Trial name
- BLAZE-2 (NCT04497987)
- Testing
- Bamlanivimab, Etesevimab
- Where
- 27 sites in United States
- Volunteers
- 1,180 people
- Sponsor
- Eli Lilly and Company
COVID-19
A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19
Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19.
- Trial name
- NCT04349631
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Hope Biosciences Research Foundation
COVID, Coronavirus
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
Our overarching goal is to improve the outcomes of critically ill COVID-19 patients with or at risk for development of acute kidney injury (AKI).
- Conditions
- COVID, Coronavirus, Coronavirus Infection, AKI
- Trial name
- NCT04530448
- Testing
- Sodium bicarbonate, Standard of Care
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- West Virginia University
COVID-19, Corona Virus Infection
Pre-exposure Prophylaxis for SARS-Coronavirus-2
Objective: To determine if pre-exposure prophylaxis with hydroxychloroquine is effective for the prevention of COVID-19 disease.
- Conditions
- COVID-19, Corona Virus Infection, ARDS, Acute Respiratory Distress Syndrome
- Trial name
- NCT04328467
- Testing
- Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 1,483 people
- Sponsor
- University of Minnesota
Covid19
COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis
A multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge
- Trial name
- NCT04650087
- Testing
- Apixaban 2.5 MG
- Where
- 121 sites in United States
- Volunteers
- 1,291 people
- Sponsor
- Thomas L. Ortel
COVID-19, SARS-CoV-2
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
The aim of the study is to assess the safety, and immunogenicity of AZD2816 for the prevention of coronavirus disease 2019 (COVID-19).
- Trial name
- AZD2816 (NCT04973449)
- Testing
- AZD1222, AZD2816
- Where
- 35 sites in Brazil, Poland and 2 more
- Volunteers
- 2,843 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19.
- Trial name
- HERO-HCQ (NCT04334148)
- Testing
- Hydroxychloroquine
- Where
- 34 sites in United States
- Volunteers
- 1,360 people, healthy volunteers welcome
- Sponsor
- Adrian Hernandez
Increased Risk of SARS-CoV-2 Infection
Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease
This is a randomized controlled trial of the efficacy and safety evaluation of oral administration of Bromhexine hydrochloride for the prevention of SARS-CoV-2 infection and COVID-19 disease in medical personnel assisting…
- Trial name
- NCT04405999
- Testing
- Bromhexine Hydrochloride
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
COVID-19
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
A multi-center adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of anti-thrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagnosis
- Trial name
- NCT04498273
- Testing
- Apixaban 2.5 MG, Apixaban 5MG, Aspirin
- Where
- 71 sites in United States
- Volunteers
- 657 people
- Sponsor
- Frank C Sciurba